Risks and benefits of everolimus

被引：0
|
作者：
Budde, Klemens [1 ]
Halleck, Fabian [1 ]
机构：
[1] Charite Univ Med Berlin, Dept Nephrol, D-10117 Berlin, Germany
来源：
TRANSPLANT INTERNATIONAL | 2019年 / 32卷 / 11期
关键词：
KIDNEY-TRANSPLANT RECIPIENTS; MYCOPHENOLATE-MOFETIL; CALCINEURIN INHIBITOR; MTOR INHIBITOR; CYTOMEGALOVIRUS; EFFICACY; SAFETY; IMMUNOSUPPRESSION; TACROLIMUS;
D O I：
10.1111/tri.13489
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
引用
收藏
页码：1124 / 1126
页数：3
相关论文
共 50 条
  • [1] Benefits and Risks of Introduction of Everolimus in Long-Term Kidney Transplant Recipients
    Asai, Toshihiro
    Tanaka, Hisao
    Nishikawa, Noriaki
    Hasaka, Tomohiro
    Kitamoto, Koichiro
    Ishii, Keiichi
    Kamikawa, Sadanori
    Sugimoto, Toshikado
    Kim, Taku
    Kumada, Norihiko
    [J]. TRANSPLANTATION, 2017, 101 (05) : S14 - S14
  • [2] Benefits and Risks of Extended Dual Antiplatelet Therapy After Everolimus-Eluting Stents
    Hermiller, James B.
    Krucoff, Mitchell W.
    Kereiakes, Dean J.
    Windecker, Stephan
    Steg, P. Gabriel
    Yeh, Robert W.
    Cohen, David J.
    Cutlip, Donald E.
    Massaro, Joseph M.
    Hsieh, Wen-Hua
    Mauri, Laura
    [J]. JACC-CARDIOVASCULAR INTERVENTIONS, 2016, 9 (02) : 138 - 147
  • [3] Benefits and risks
    [J]. Canadian Mining Journal, 2023, 144 (05) : 16 - 18
  • [4] RISKS AND BENEFITS
    HAGGERTY, LM
    [J]. HUMANE MEDICINE, 1987, 3 (01) : 71 - 71
  • [5] Risks and benefits
    [J]. Nature Nanotechnology, 2006, 1 : 151 - 151
  • [6] RISKS AND BENEFITS
    TIPPEE, B
    [J]. OIL & GAS JOURNAL, 1981, 79 (25) : 15 - 15
  • [7] Risks and benefits
    Novack, GD
    [J]. OCULAR SURFACE, 2006, 4 (01): : 58 - 60
  • [8] BENEFITS AND RISKS
    不详
    [J]. NATURE, 1973, 246 (5427) : 9 - 10
  • [9] Risks and benefits
    不详
    [J]. NATURE NANOTECHNOLOGY, 2006, 1 (03) : 151 - 151
  • [10] Placebos, Full Disclosure, and Trust: The Risks and Benefits of Disclosing Risks and Benefits
    Schwartz, Peter H.
    [J]. AMERICAN JOURNAL OF BIOETHICS, 2015, 15 (10): : 13 - 14
12345